ESTHER
CONDE GALLEGO
Profesora asociada de Ciencias de la Salud
FERNANDO
LÓPEZ-RÍOS MORENO
Profesor asociado de Ciencias de la Salud
Publikationen, an denen er mitarbeitet FERNANDO LÓPEZ-RÍOS MORENO (37)
2024
-
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
-
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049
2023
-
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562
-
Caracterización y clasificación molecular del cáncer de pulmón
Revisiones en Cancer, Vol. 37, Núm. 3, pp. 114-120
-
Pan-TRK Immunohistochemistry to Optimize the Detection of NTRK Fusions: Removing the Hay When Looking for the Needle
Modern Pathology
2022
2021
-
Erratum: Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients with NTRK Fusion Cancer (Arch Pathol Lab Med (2021) 145: 4 (441–447) DOI: 10.5858/arpa.2020-0042-OA)
Archives of Pathology and Laboratory Medicine
-
Pan-TRK immunohistochemistry an example-based practical approach to efficiently identify patients with NTRK fusion cancer
Archives of Pathology and Laboratory Medicine, Vol. 145, Núm. 8, pp. 1031-1040
-
Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody
Expert Review of Molecular Diagnostics, Vol. 21, Núm. 5, pp. 437-444
-
Targeted therapy moves to earlier stages of non-small-cell lung cancer: Emerging evidence, controversies and future challenges
Future Oncology, Vol. 17, Núm. 30, pp. 4011-4025
2020
-
Immunotherapy moves to the early-stage setting in non-small cell lung cancer: Emerging evidence and the role of biomarkers
Cancers, Vol. 12, Núm. 11, pp. 1-21
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 167-181
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 22, Núm. 7, pp. 989-1003
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2018
-
Aligning digital CD8
+
scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma
Histopathology, Vol. 72, Núm. 2, pp. 270-284
2017
-
Identification of ALK, ROS1, and RET fusions by a multiplexed mRNA-based assay in formalin-fixed, paraffin-embedded samples from advanced non-small-cell lung cancer patients
Clinical Chemistry, Vol. 63, Núm. 3, pp. 751-760
2016
-
Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas
Expert Review of Molecular Diagnostics, Vol. 16, Núm. 6, pp. 707-713
2015
-
The anaplastic lymphoma kinase testing conundrum
Expert Review of Molecular Diagnostics, Vol. 15, Núm. 2, pp. 161-163